Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK-9) Inhibitors Induced Liver Injury - A Retrospective Analysis

Journal of Community Hospital Internal Medicine Perspectives- United Kingdom

doi 10.1080/20009666.2019.1710952

Full Text

Abstract

Available in

Categories

Internal Medicine

Date

January 2, 2020

Authors

Mamoon-Ur- Rashid

Muhammad Shayan Khan

Publisher

Informa UK Limited

Related search

Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Clinical Research in Cardiology Supplements

Nuclear Medicine

Molecular Biology

Structural Biology

English

Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9

Journal of Thoracic Disease

Respiratory Medicine

English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine

English

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Do We Have a Vanquishing New Strategy?

European Journal of Preventive Cardiology

Cardiovascular Medicine

English

Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Cardiovascular Medicine

English

PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6)

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Cancer Research

English

Fasting Reduces Plasma Proprotein Convertase, Subtilisin/Kexin Type 9 and Cholesterol Biosynthesis in Humans

Journal of Lipid Research

English

Variations of the Proprotein Convertase Subtilisin/Kexin Type 9 Gene in Coronary Artery Disease

Journal of International Medical Research

English

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke

Circulation. Genomic and precision medicine

Cardiovascular Medicine

English